1) POET is in need of fundings. Read the latest and MD&A and FS.
2) Denselight (Singapore's operation), from 2016 and up to June 30, 2019, has generated a compounded net loss of $10.5M and was (as I understand it) POET's R&D hub.
3) Book value of Denselight is lower than the proposed sale amount and that despite the historical net losses incurred by Denselight. We, as shareholders, are getting a premium and the buyer is hereby paying for a yet to be realized potential.
4) The buyer of Denselight is recognizing that Denselight is not generating positive cash-flows and will disburse more funds in turning it around.
5) It is my impression that there is more than meet the eye. The acquiring consortium is pouring some serious hard dollars in this acquisition. They have to be confident that Denselight will turn-around from a R&D hub to a money-making manufacturing plant.
LoIt